Numis Securities Ltd Reiterates “Buy” Rating for Indivior PLC (INDV)

Numis Securities Ltd reiterated their buy rating on shares of Indivior PLC (LON:INDV) in a research note published on Thursday. They currently have a GBX 450 ($5.57) price target on the specialty pharmaceutical company’s stock.

INDV has been the subject of several other reports. Jefferies Group boosted their price objective on shares of Indivior PLC from GBX 330 ($4.09) to GBX 370 ($4.58) and gave the stock a buy rating in a research note on Monday, August 22nd. Deutsche Bank AG decreased their price objective on shares of Indivior PLC from GBX 400 ($4.95) to GBX 395 ($4.89) and set a buy rating for the company in a research note on Tuesday, October 4th. Royal Bank Of Canada boosted their price objective on shares of Indivior PLC from GBX 185 ($2.29) to GBX 325 ($4.03) and gave the stock a sector performer rating in a research note on Tuesday, August 9th. Morgan Stanley boosted their price objective on shares of Indivior PLC from GBX 280 ($3.47) to GBX 330 ($4.09) and gave the stock an overweight rating in a research note on Monday, August 1st. Finally, Stifel Nicolaus reiterated a buy rating and set a GBX 350 ($4.34) price objective on shares of Indivior PLC in a research note on Friday, July 29th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of GBX 369.29 ($4.57).

Analyst Recommendations for Indivior PLC (LON:INDV)

Indivior PLC (LON:INDV) opened at 371.40 on Thursday. The firm’s market capitalization is GBX 2.64 billion. Indivior PLC has a 1-year low of GBX 126.60 and a 1-year high of GBX 377.00. The firm has a 50-day moving average of GBX 319.90 and a 200-day moving average of GBX 264.58.

About Indivior PLC

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of prescription drugs that are based on buprenorphine for treatment of opioid dependence segment. The Company’s treatment and pipeline focuses on opioid use disorder, alcohol use disorder, overdose rescue and co-morbidities of addiction/schizophrenia.

Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2016 Mideast Time.